ALLR · XBRL financial data
Allarity Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ALLR's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Gross profit | — | (2,265) | — | — | — |
| Research and development | 14,196 | 6,930 | 7,103 | 6,096 | 6,601 |
| General and administrative | 12,360 | 9,962 | 10,026 | 11,442 | 6,324 |
| Total operating expenses | 26,556 | 34,463 | 17,129 | 27,241 | 12,925 |
| Operating income (loss) | (26,556) | (34,463) | (17,129) | (27,241) | (12,605) |
| Interest income | — | 30 | 22 | 533 | 801 |
| Interest expense | 99 | 12 | 498 | 653 | 185 |
| Other income (expense) | 41 | — | — | — | — |
| Income tax expense (benefit) | 133 | (1,521) | 83 | (381) | 0 |
| Net income (loss) | (26,648) | (16,058) | (11,901) | (24,515) | (11,231) |
| Earnings per share, basic USD per share | (4.19) | (2.21) | (10.26) | (15.65) | (0.78) |
| Earnings per share, diluted USD per share | (4.19) | (2.21) | (10.26) | — | — |
| Weighted average shares, basic thousands of shares | 6,359 | 9,527 | 1,991 | 1,607 | 14,379 |
| Weighted average shares, diluted thousands of shares | 6,359 | 9,527 | 1,991 | — | — |
- † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ALLR's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 19,555 | 2,029 | 166 | 19,533 | 14,687 |
| Total current assets | 21,054 | 4,968 | 1,971 | 22,341 | 17,928 |
| Property and equipment, net | 8 | 21 | 20 | 309 | 330 |
| Right-of-use asset | 86 | 6 | — | — | — |
| Total assets | 49,633 | 14,544 | 11,862 | 22,650 | 18,258 |
| Accounts payable | 698 | 6,251 | 8,416 | 4,182 | 4,282 |
| Accrued liabilities | 8,590 | 1,904 | 1,309 | 5,232 | 2,667 |
| Total current liabilities | 20,719 | 11,222 | 14,167 | 10,839 | 8,430 |
| Lease liability, non-current | 9 | — | — | — | — |
| Total liabilities | 30,849 | 12,654 | 14,613 | 10,839 | 8,430 |
| Accumulated deficit | (66,492) | (82,550) | (94,451) | (118,966) | (130,197) |
| Total stockholders' equity | 18,152 | (113) | (2,751) | 11,811 | 9,828 |
| Total liabilities and equity | 49,633 | 14,544 | 11,862 | 22,650 | 18,258 |
| Common shares outstanding (cover page) thousands of shares | 8,842 | ≈30,000 | 6,179 | 17,015 | 15,819 |
- ≈ Rounded on cover: the filing states this count rounded, and it sits more than 1% off the weighted shares for the period.
- † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ALLR's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (26,648) | (16,058) | (11,901) | (24,515) | (11,231) |
| Stock-based compensation | 6,368 | 1,752 | (71) | 71 | 482 |
| Depreciation and amortization | 106 | 60 | 37 | 9 | — |
| Net cash from operating activities | (15,050) | (16,817) | (12,745) | (17,352) | (14,820) |
| Purchases of property and equipment | — | 18 | 0 | 298 | 8 |
| Net cash from investing activities | 1,000 | 791 | 0 | (298) | (8) |
| Proceeds from issuing common stock | 32,125 | — | 0 | 37,354 | 11,143 |
| Share repurchases | — | — | — | 0 | 3,190 |
| Net cash from financing activities | 33,819 | (1,311) | 10,995 | 36,792 | 10,648 |
| Net change in cash | 19,769 | (17,337) | — | — | — |
- † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Allarity Therapeutics | 16,982 | not reported | (2,564)* | 15.9M | 6.6 quarters | 10-QJun 30, 2026 |
| X4 Pharmaceuticals | 185,801 | 2,879 | (20,186)* | 102.1M | 9.2 quarters | 10-QSep 30, 2026 |
| Akari Therapeutics | 7,694 | not reported | (3,109)* | 155.8B | 2.5 quarters | 10-QJun 30, 2026 |
| ProPhase Labs | 20 | 1,011 | (78)* | 15.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Pluri | 3,529 | 335* | (4,443)* | 12.3M | 0.8 quarters | 10-KJun 30, 2026 |
| Edesa Biotech | 10,300 | not reported | (3,083)* | 9.6M | 3.3 quarters | 10-QJun 30, 2026 |
| CalciMedica | 18,617 | not reported | (4,620)* | 34.1M | 4.0 quarters | 10-QJun 30, 2026 |
| GeoVax Labs | 3,143 | not reported | (3,658)* | 7.4M | 0.9 quarters | 10-QJun 30, 2026 |
| Earth Science Tech | 631 | 9,026 | 707 | 287.6M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.